Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
AssigneeEli Lilly and Company
InventorsMythili KONERU, Maria de las Nieves VELEZ DE MENDIZABAL CASTILLO
Life of this patent
Estimating the term…
Abstract
The present invention relates to dosing regimens for antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (TIM-3), and may be useful for treating tumors in combination with anti-human PD-L1 antibodies, anti-human PD-1 antibodies, chemotherapy, and ionizing radiation as well as the use of said antibodies for the treatment of solid tumors that are mismatch repair deficient or exhibit a high degree of microsatellite instability.
Claims34
A method of treating cancer comprising administering an anti-human TIM-3 antibody to a human patient in need thereof with a dose in the range of 1 mg to 1800 mg, wherein the anti-human TIM-3 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:
- 10 and a heavy chain having the amino acid sequence of SEQ ID NO:
- 11.
-13. (canceled)
(canceled)
(canceled)
-35. (canceled)
-39. (canceled)
-150. (canceled)
Dependencies are inferred from the claim text.